MCID: HND002
MIFTS: 51

Hand, Foot and Mouth Disease

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Hand, Foot and Mouth Disease

MalaCards integrated aliases for Hand, Foot and Mouth Disease:

Name: Hand, Foot and Mouth Disease 12 74 43 15 17
Vesicular Stomatitis and Exanthem 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10881
ICD9CM 34 074.3
MeSH 43 D006232
NCIt 49 C128439
SNOMED-CT 67 67171006
ICD10 32 B08.4
UMLS 71 C0018572

Summaries for Hand, Foot and Mouth Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Human coxsackievirus A16 or has material basis in Human enterovirus 71, which are transmitted by contaminated fomites, and transmitted by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has symptom fever, has symptom poor appetite, has symptom malaise, has symptom sore throat, has symptom painful sores in the mouth, and has symptom skin rash on the palms of the hands and soles of the feet.

MalaCards based summary : Hand, Foot and Mouth Disease, also known as vesicular stomatitis and exanthem, is related to encephalitis and poliomyelitis, and has symptoms including fever, poor appetite and sore throat. An important gene associated with Hand, Foot and Mouth Disease is SCARB2 (Scavenger Receptor Class B Member 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Hand, foot, and mouth disease (HFMD) is a common infection caused by a group of viruses. It typically... more...

Related Diseases for Hand, Foot and Mouth Disease

Diseases related to Hand, Foot and Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.5 TLR3 IL6 IL10 DDX58
2 poliomyelitis 31.4 SCARB2 IL10 IFNG
3 herpangina 31.0 TLR7 TLR4 TLR3 IL6 IL10 DDX58
4 chickenpox 31.0 TLR3 IL6 IL10 IFNG
5 myocarditis 30.9 TLR4 TLR3 IL6 IL10 IFNG
6 viral encephalitis 30.9 TLR3 IL6 IL10
7 stomatitis 30.8 TLR4 IL6 IL10 IFNG DDX58
8 chorioretinitis 30.8 IL6 IL10 IFNG
9 acute transverse myelitis 30.8 IL6 IL10
10 dermatitis 30.7 TLR4 IL6 IL13 IL10 IFNG
11 aphthous stomatitis 30.6 TLR4 IL6 IL10 IFNG
12 bronchopneumonia 30.5 TLR4 IL6 IL10
13 diarrhea 30.5 TLR4 IL6 IL10 IFNG
14 graft-versus-host disease 30.5 IL6 IL10 IFNG
15 posterior uveitis 30.5 IL6 IL13 IFNG
16 chlamydia 30.5 TLR4 IL6 IL10 IFNG
17 meningitis 30.5 TLR4 S100B IL6 IL10 IFNG
18 rhinitis 30.5 IL6 IL13 IL10 IFNG
19 plague 30.3 TLR4 IL6 IL10 DDX58
20 endocarditis 30.3 IL6 IL10 IFNG
21 appendicitis 30.3 TLR4 IL6 IL10 IFNG
22 tetanus 30.2 IL6 IL13 IL10 IFNG
23 hepatitis a 30.2 TLR4 TLR3 IL10 IFNG
24 measles 30.2 TLR7 TLR4 TLR3 OAS1 IL6 IFNG
25 gaucher's disease 30.2 SCARB2 IL6 GBA
26 tonsillitis 30.0 TLR4 TLR3 IL6 IL10 IFNG
27 viral hepatitis 30.0 TLR4 TLR3 IL6 IL10 IFNG
28 dermatitis, atopic 29.9 TLR7 TLR4 TLR3 IL6 IL13 IL10
29 nervous system disease 29.8 MIR221 MIR150 IL6 IFNG
30 skin disease 29.6 TLR4 S100B IL6 IL13 IL10 IFNG
31 bronchiolitis 29.5 TLR7 TLR4 TLR3 IL6 IL13 IL10
32 viral infectious disease 29.5 TLR7 TLR4 TLR3 OAS1 IL6 IL13
33 mouth disease 29.4 TLR7 TLR4 TLR3 SCARB2 SCARA3 S100B
34 central nervous system disease 29.3 MIR221 MIR150 IL6 IFNG
35 exanthem 10.9
36 pulmonary edema 10.8
37 aseptic meningitis 10.8
38 cytokine deficiency 10.5
39 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
40 spotted fever rickettsiosis 10.5 IL10 IFNG
41 hyperglycemia 10.5
42 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 IL13
43 prosthetic joint infection 10.5 TLR4 IL6
44 myoclonus 10.4
45 b-cell growth factor 10.4 IL6 IFNG
46 erythema multiforme 10.4
47 myelitis 10.4
48 chronic graft versus host disease 10.4 IL10 IFNG
49 eales disease 10.4 IL6 IL10 IFNG
50 west nile virus 10.4 TLR3 OAS1 DDX58

Graphical network of the top 20 diseases related to Hand, Foot and Mouth Disease:



Diseases related to Hand, Foot and Mouth Disease

Symptoms & Phenotypes for Hand, Foot and Mouth Disease

Symptoms:

12
  • fever
  • poor appetite
  • sore throat
  • malaise
  • painful sores in the mouth
  • skin rash on the palms of the hands

GenomeRNAi Phenotypes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.14 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.14 C4A C4B ANKRD17 SCARA3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.14 C4A C4B IL10 TLR4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.14 TLR4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.14 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.14 IL10 TLR4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.14 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.14 C4A C4B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.14 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.14 C4A C4B IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.14 TLR4 SCARA3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.14 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.14 SCARA3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.14 ANKRD17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.14 C4A C4B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.14 SCARA3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.14 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.14 SCARA3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.14 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.14 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.14 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.14 ANKRD17
23 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.14 SCARA3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.14 SCARA3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.14 ANKRD17
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.14 C4A C4B SCARA3
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.14 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.14 C4A C4B
29 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.14 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.14 ANKRD17
31 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.14 C4A C4B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.14 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.14 IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.14 IL10

MGI Mouse Phenotypes related to Hand, Foot and Mouth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ANKRD17 C4B DDX58 GBA IFNG IL10
2 hematopoietic system MP:0005397 10.15 C4B DDX58 FUBP1 GBA IFNG IL10
3 cardiovascular system MP:0005385 10.1 ANKRD17 C4B FUBP1 GBA IFNG IL10
4 immune system MP:0005387 10.03 C4B DDX58 FUBP1 GBA IFNG IL10
5 mortality/aging MP:0010768 9.8 ANKRD17 C4B DDX58 FUBP1 GBA IFNG
6 liver/biliary system MP:0005370 9.76 C4B DDX58 FUBP1 GBA IFNG IL10
7 respiratory system MP:0005388 9.23 FUBP1 GBA IFNG IL10 IL13 IL6

Drugs & Therapeutics for Hand, Foot and Mouth Disease

Drugs for Hand, Foot and Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Antibodies, Blocking Phase 4
4 Anti-Infective Agents Phase 4
5 Antiviral Agents Phase 4
6 Antimetabolites Phase 4
7 Immunoglobulins Phase 4
8 Antibodies Phase 4
9 Vaccines Phase 4
10 Immunologic Factors Phase 4
11
Ibuprofen Approved Phase 2 15687-27-1 3672
12
Acetaminophen Approved Phase 2 103-90-2 1983
13
Sucralfate Approved Phase 2 54182-58-0
14
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
16
Aluminum sulfate Approved Phase 2 10043-01-3
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
18
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
19 Pharmaceutical Solutions Phase 2
20 Anti-Inflammatory Agents Phase 2
21 Analgesics, Non-Narcotic Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 2
23 Antipyretics Phase 2
24 Cyclooxygenase Inhibitors Phase 2
25 Antirheumatic Agents Phase 2
26 Gastrointestinal Agents Phase 2
27 Hormones Phase 2
28 Analgesics Phase 2
29 Tocolytic Agents Phase 2
30 Anti-Arrhythmia Agents Phase 2
31 retinol Phase 2
32 Retinol palmitate Phase 2
33 Anesthetics Phase 2
34 Anticonvulsants Phase 2
35 Central Nervous System Depressants Phase 2
36 calcium channel blockers Phase 2
37 Calcium, Dietary Phase 2
38 Anti-Ulcer Agents Phase 2
39 Antacids Phase 2
40 Adjuvants, Immunologic Phase 2
41
Suramin Investigational Phase 1 145-63-1 5361
42 Antiparasitic Agents Phase 1
43 Antiprotozoal Agents Phase 1
44 Anthelmintics Phase 1
45
Methylprednisolone hemisuccinate Approved 2921-57-5
46
Methylprednisolone Approved, Vet_approved 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved 302-25-0
48 Prednisolone acetate Approved, Vet_approved 52-21-1
49
Prednisolone Approved, Vet_approved 50-24-8 5755
50 Grape Approved

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
4 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
5 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
6 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
7 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
8 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
9 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
10 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
11 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
12 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Active, not recruiting NCT02999828 Phase 4
13 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
14 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
15 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
16 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
17 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
18 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
19 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Active, not recruiting NCT03909074 Phase 3
20 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
21 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
22 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
23 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
24 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
25 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
26 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
27 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
28 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
29 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
30 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
31 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
32 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
33 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
34 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
35 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
36 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
37 Long Term Outcomes of EV71 Central Nervous System Infection Unknown status NCT00172393
38 Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study Completed NCT01769794 Western therapy;JET;Placebo(for JET)
39 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease Completed NCT01554930 Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge);Xiyanping injection plus western therapy
40 An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT02001233
41 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Completed NCT01182532 TCM Syndrome Differentiation and Treatment
42 Phase IV, Open-labelled, Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT03281174
43 A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease Completed NCT02066714
44 Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children Completed NCT01255124
45 Do Traditional or Flavored Tongue Depressors Make for Easier Posterior Completed NCT03095183
46 Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Not yet recruiting NCT03759470

Search NIH Clinical Center for Hand, Foot and Mouth Disease

Cochrane evidence based reviews: hand, foot and mouth disease

Genetic Tests for Hand, Foot and Mouth Disease

Anatomical Context for Hand, Foot and Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Hand, Foot and Mouth Disease:

19
Skin

MalaCards organs/tissues related to Hand, Foot and Mouth Disease:

40
Skin, Brain, T Cells, B Cells, Testes, Lung, Eye

Publications for Hand, Foot and Mouth Disease

Articles related to Hand, Foot and Mouth Disease:

(show top 50) (show all 2017)
# Title Authors PMID Year
1
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
2
Association of polymorphisms in the vitamin D receptor gene with susceptibility to and severity of hand, foot, and mouth disease caused by coxsackievirus A16. 61
31587312 2020
3
The spatial heterogeneity of the associations between relative humidity and pediatric hand, foot and mouth disease: Evidence from a nation-wide multicity study from mainland China. 61
31874401 2020
4
Hand-foot-and-mouth disease in uruguay: Coxsackievirus A6 identified as causative of an outbreak in a rural childcare center. 61
31502682 2020
5
Protective Immunity Elicited by VP1 Chimeric Antigens of Bacterial Ghosts against Hand-Foot-and-Mouth Disease Virus. 61
32024212 2020
6
Reversible Cerebral Angiopathy after Viral Infection in a Pediatric Patient with Genetic Variant of RNF213. 61
31818681 2020
7
Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. 61
31892446 2020
8
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease. 61
31961293 2020
9
Genetic characterization of VP1 of coxsackieviruses A2, A4, and A10 associated with hand, foot, and mouth disease in Vietnam in 2012-2017: endemic circulation and emergence of new HFMD-causing lineages. 61
32008121 2020
10
Non-polio enteroviruses among healthy children in the Philippines. 61
32013921 2020
11
Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. 61
31911601 2020
12
Pathogenic characteristics of hand, foot and mouth disease in Shaanxi Province, China, 2010-2016. 61
31969644 2020
13
Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by Coxsackievirus A6. 61
31683008 2020
14
Atypical hand-foot-and-mouth disease. 61
31959658 2020
15
The epidemiological characteristics and spatio-temporal analysis of childhood hand, foot and mouth disease in Korea, 2011-2017. 61
31931518 2020
16
Spatial heterogeneity of the association between temperature and hand, foot, and mouth disease risk in metropolitan and other areas. 61
31954246 2020
17
Hand, foot and mouth disease caused by Coxsackie viruses A6 and A16 in Assam, Northeast India: A need for surveillance. 61
30860171 2020
18
Coxsackievirus A6 infection presenting with different clinical phenotypes of hand-foot-and-mouth disease in two brothers at the same time. 61
31957699 2020
19
Clinical and epidemiological characteristics of Coxsackievirus A6- and Enterovirus 71-associated clinical stage 2 and 3 severe hand, foot, and mouth disease in Guangxi, Southern China, 2017. 61
31629866 2020
20
Hand, foot, and mouth disease in Changsha City, China, 2009-2017: a new method to analyse the epidemiological characteristics of the disease. 61
31596157 2020
21
Newly emerged enterovirus-A71 C4 sublineage may be more virulent than B5 in the 2015-2016 hand-foot-and-mouth disease outbreak in northern Vietnam. 61
31932599 2020
22
Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease. 61
31939669 2020
23
Multi-modal Diagnosis of Infectious Diseases in the Developing World. 61
31944967 2020
24
Downregulation of miR-155-5p facilitates enterovirus 71 replication through suppression of type I IFN response by targeting FOXO3/IRF7 pathway. 61
31856677 2020
25
Impact of Ambient Temperature and Relative Humidity on the Incidence of Hand-Foot-Mouth Disease in Wuhan, China. 61
31936369 2020
26
Salvianolic Acid B Inhibits Hand-Foot-Mouth Disease Enterovirus 71 Replication through Enhancement of AKT Signaling Pathway. 61
31752055 2020
27
Next generation sequencing of human enterovirus strains from an outbreak of enterovirus A71 shows applicability to outbreak investigations. 61
31790967 2020
28
Estimation of the reproduction number and identification of periodicity for HFMD infections in northwest China. 61
31568791 2020
29
Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. 61
32027857 2020
30
Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. 61
32004757 2020
31
Exosomes from EV71-infected oral epithelial cells can transfer miR-30a to promote EV71 infection. 61
31958204 2020
32
Acute enterovirus infections significantly alter host cellular DNA methylation status. 61
31927072 2020
33
A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. 61
31944333 2020
34
One-Step Monitoring of Multiple Enterovirus 71 Infection-Related MicroRNAs Using Core-Satellite Structure of Magnetic Nanobeads and Multicolor Quantum Dots. 61
31762266 2020
35
Establishment of Asia-Pacific Network for Enterovirus Surveillance. 61
31679864 2020
36
Cellular receptors for enterovirus A71. 61
31924205 2020
37
Characterization of inflammatory cytokine profiles in cerebrospinal fluid of hand, foot, and mouth disease children with enterovirus 71-related encephalitis in Hangzhou, Zhejiang, China. 61
31876729 2019
38
Seasonality of the transmissibility of hand, foot and mouth disease: a modelling study in Xiamen City, China. 61
31884976 2019
39
Clinical and Molecular Investigations of Hand, Foot and Mouth Disease Outbreak in Navi Mumbai, India. 61
31884439 2019
40
Weather effects on hand, foot, and mouth disease at individual level: a case-crossover study. 61
31796004 2019
41
Interplays between Enterovirus A71 and the innate immune system. 61
31787104 2019
42
Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10. 61
31851566 2019
43
Multiple divergent Human mastadenovirus C co-circulating in mainland of China. 61
31505276 2019
44
Mechanism for the lethal effect of enterovirus A71 intracerebral injection in neonatal mice. 61
31857694 2019
45
A 5-year molecular epidemiology survey of human enterovirus 71 before vaccine application in Yunnan Province, China. 61
31850595 2019
46
Process optimization for the rapid production of Enterovirus 71. 61
31559514 2019
47
Global Gene Expression Analysis of the Brainstem in EV71- and CVA16-Infected Gerbils. 61
31906004 2019
48
Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. 61
31870905 2019
49
Early evidence of inactivated enterovirus 71 vaccine impact against hand, foot, and mouth disease in a major center of ongoing transmission in China, 2011-2018: a longitudinal surveillance study. 61
31879754 2019
50
Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice. 61
31570994 2019

Variations for Hand, Foot and Mouth Disease

Expression for Hand, Foot and Mouth Disease

Search GEO for disease gene expression data for Hand, Foot and Mouth Disease.

Pathways for Hand, Foot and Mouth Disease

Pathways related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 TLR7 TLR4 TLR3 S100B OAS1 IL6
2
Show member pathways
12.9 TLR7 TLR4 TLR3 OAS1 IL6 IL10
3
Show member pathways
12.8 IL6 IL13 IL10 IFNG C4A
4 12.74 TLR3 OAS1 IL6 IFNG DDX58
5
Show member pathways
12.65 TLR4 TLR3 S100B IL6 IFNG DDX58
6
Show member pathways
12.57 TLR7 TLR4 TLR3 OAS1 IL6 IFNG
7
Show member pathways
12.53 TLR4 IL6 IL13 IL10 IFNG
8 12.4 TLR7 TLR3 OAS1 IL10 IFNG DDX58
9
Show member pathways
12.3 IL6 IL13 IL10 IFNG
10
Show member pathways
12.27 TLR4 TLR3 IL6 IFNG
11
Show member pathways
12.22 TLR7 TLR4 TLR3 IL6
12
Show member pathways
12.2 OAS1 IL6 IL13 IL10 IFNG
13 12.19 TLR4 IL6 IL10 IFNG
14
Show member pathways
12.14 TLR7 TLR4 IL6 IFNG
15 12.07 TLR7 TLR4 TLR3 IL6 IFNG
16 12.04 IL6 IL13 IL10 C4B C4A
17
Show member pathways
11.97 TLR4 IL6 IL13 IFNG
18
Show member pathways
11.95 TLR7 TLR4 TLR3 IL13
19 11.83 TLR4 IL6 IL10 IFNG
20 11.82 TLR4 IL6 IFNG
21 11.77 TLR7 TLR4 TLR3
22 11.75 IL6 IL13 IFNG
23 11.73 TLR4 IL6 IFNG
24 11.73 IL13 IL10 IFNG
25 11.66 TLR7 IL6 IL10 IFNG
26 11.63 IL6 IL13 IL10 IFNG
27 11.49 IL6 IL13 IL10
28 11.47 MIR221 MIR150 IL6
29 11.45 IL13 IL10 IFNG
30 11.33 IL6 IL10 IFNG
31 11.3 TLR4 IL6 IL10
32 11.26 TLR4 IL6 IL10 IFNG
33 11.23 IL6 IL13 IFNG
34 11.23 TLR4 IL6 IL10 C4B C4A
35
Show member pathways
11.21 TLR7 TLR4 TLR3 IL6 IL10 IFNG
36 11.13 IL13 IL10 IFNG
37 10.92 IL6 IL13 IL10 IFNG

GO Terms for Hand, Foot and Mouth Disease

Cellular components related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.44 TLR3 SCARA3 S100B MIR576 MIR221 MIR150
2 endosome membrane GO:0010008 9.26 TLR7 TLR4 TLR3 SCARB2

Biological processes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.05 TLR7 TLR4 OAS1 IL6 IL13 IL10
2 immune system process GO:0002376 10.03 TLR7 TLR4 TLR3 OAS1 DDX58 C4B
3 positive regulation of gene expression GO:0010628 10.02 TLR4 TLR3 IL6 IL13 IFNG FUBP1
4 defense response to bacterium GO:0042742 9.97 TLR4 TLR3 IL10 ANKRD17
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.93 TLR4 TLR3 S100B ANKRD17
6 response to virus GO:0009615 9.89 TLR3 OAS1 IFNG DDX58
7 defense response to virus GO:0051607 9.88 TLR7 TLR3 OAS1 IL6 IFNG DDX58
8 cellular response to mechanical stimulus GO:0071260 9.86 TLR7 TLR4 TLR3 IL13
9 positive regulation of inflammatory response GO:0050729 9.85 TLR7 TLR4 TLR3
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 MIR221 IL6 IL13 IFNG
11 response to glucocorticoid GO:0051384 9.83 S100B IL6 IL10
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.82 TLR7 TLR4 TLR3
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TLR7 TLR4 TLR3
14 toll-like receptor signaling pathway GO:0002224 9.79 TLR7 TLR4 TLR3
15 negative regulation of interleukin-6 production GO:0032715 9.78 TLR4 IL10 GBA
16 positive regulation of JAK-STAT cascade GO:0046427 9.77 MIR221 IL6 IL10
17 positive regulation of interleukin-12 production GO:0032735 9.76 TLR4 TLR3 IFNG
18 positive regulation of interferon-beta production GO:0032728 9.75 TLR4 TLR3 DDX58
19 positive regulation of macrophage activation GO:0043032 9.72 TLR4 IL13 IL10
20 I-kappaB phosphorylation GO:0007252 9.7 TLR7 TLR4 TLR3
21 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 TLR7 TLR4
22 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.68 TLR7 TLR3
23 toll-like receptor 3 signaling pathway GO:0034138 9.67 TLR3 SCARA3
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 TLR4 IL10 IFNG
25 microglial cell activation GO:0001774 9.67 TLR7 TLR3 IL13 IFNG
26 positive regulation of interferon-alpha production GO:0032727 9.66 TLR4 DDX58
27 positive regulation of chemokine biosynthetic process GO:0045080 9.66 TLR3 IFNG
28 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.65 MIR221 IL10
29 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.64 TLR4 TLR3
30 positive regulation of apoptotic cell clearance GO:2000427 9.63 C4B C4A
31 positive regulation of interferon-beta biosynthetic process GO:0045359 9.63 TLR7 TLR4 TLR3
32 detection of virus GO:0009597 9.62 TLR3 DDX58
33 positive regulation of interleukin-8 production GO:0032757 9.62 TLR7 TLR4 TLR3 DDX58
34 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.61 TLR7 TLR3
35 regulation of dendritic cell cytokine production GO:0002730 9.57 TLR4 TLR3
36 positive regulation of chemokine production GO:0032722 9.56 TLR7 TLR4 TLR3 IL6
37 inflammatory response GO:0006954 9.56 TLR7 TLR4 TLR3 IL6 IL13 IL10
38 positive regulation of interleukin-6 production GO:0032755 9.55 TLR7 TLR4 TLR3 IL6 DDX58
39 innate immune response GO:0045087 9.28 TLR7 TLR4 TLR3 S100B OAS1 DDX58

Molecular functions related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 IL6 IL13 IL10 IFNG
2 transmembrane signaling receptor activity GO:0004888 9.26 TLR7 TLR4 TLR3 SCARB2
3 double-stranded RNA binding GO:0003725 8.92 TLR7 TLR3 OAS1 DDX58

Sources for Hand, Foot and Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....